144 related articles for article (PubMed ID: 11037052)
1. The distribution of the major peripheral blood T, B and NK cell subsets does not predict the clinical outcome of Graves' disease patients after methimazole therapy.
Corrales JJ; López A; Ciudad J; Orfao A
J Biol Regul Homeost Agents; 2000; 14(3):193-9. PubMed ID: 11037052
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulation by methimazole therapy in Graves' disease: rapid changes in activation stage of circulating regulatory T cell subsets, B cells and NK cells.
Karlsson FA; Tötterman TH
Clin Exp Immunol; 1988 Nov; 74(2):258-63. PubMed ID: 2906281
[TBL] [Abstract][Full Text] [Related]
3. Methimazole treatment in Graves' disease: behaviour of CD5+B lymphocytes and regulatory T cell subsets.
Paggi A; Amoroso A; Ferri GM; Mariotti A; Pellegrino C; Afeltra A
Eur Rev Med Pharmacol Sci; 1998; 2(1):11-9. PubMed ID: 9825565
[TBL] [Abstract][Full Text] [Related]
4. Methimazole therapy in Graves' disease influences the abnormal expression of CD69 (early activation antigen) on T cells.
Corrales JJ; López A; Ciudad J; Mories MT; Miralles JM; Orfao A
J Endocrinol; 1997 Dec; 155(3):491-500. PubMed ID: 9487994
[TBL] [Abstract][Full Text] [Related]
5. Remission of Graves' hyperthyroidism treated with methimazole.
Bolaños F; González-Ortiz M; Durón H; Sánchez C
Rev Invest Clin; 2002; 54(4):307-10. PubMed ID: 12415954
[TBL] [Abstract][Full Text] [Related]
6. Abnormal distribution of gammadelta T lymphocytes in Graves' disease and insulin-dependent diabetes type 1.
Kretowski A; Myśliwiec J; Kinalska I
Arch Immunol Ther Exp (Warsz); 2000; 48(1):39-42. PubMed ID: 10722230
[TBL] [Abstract][Full Text] [Related]
7. Analysis of recently activated, memory and naive lymphocyte T subsets in the peripheral blood of patients with Graves' disease and insulin-dependent diabetes mellitus.
Kretowski A; Myśliwiec J; Turowski D; Wysocka J; Kinalska I
Rocz Akad Med Bialymst; 1999; 44():226-34. PubMed ID: 10697437
[TBL] [Abstract][Full Text] [Related]
8. [Effect of thyroxine upon prevention of recurrence of Graves' disease treated with antithyroid drugs].
Wu G; Jie Y; Situ Y
Zhonghua Yi Xue Za Zhi; 2001 Mar; 81(5):274-5. PubMed ID: 11798886
[TBL] [Abstract][Full Text] [Related]
9. Analysis of circulating T gamma/delta lymphocytes and CD16/56 cell populations in children and adolescents with Graves' disease.
Bossowski A; Urban M; Stasiak-Barmuta A
Pediatr Res; 2003 Sep; 54(3):425-9. PubMed ID: 12761360
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of the interferon-gamma-inducible alpha chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy.
Antonelli A; Fallahi P; Rotondi M; Ferrari SM; Serio M; Miccoli P
Br J Surg; 2006 Oct; 93(10):1226-31. PubMed ID: 16838393
[TBL] [Abstract][Full Text] [Related]
11. Use of an artificial neural network to predict Graves' disease outcome within 2 years of drug withdrawal.
Orunesu E; Bagnasco M; Salmaso C; Altrinetti V; Bernasconi D; Del Monte P; Pesce G; Marugo M; Mela GS
Eur J Clin Invest; 2004 Mar; 34(3):210-7. PubMed ID: 15025680
[TBL] [Abstract][Full Text] [Related]
12. Antithyroid drug-induced immunomodulation in Graves' disease patients.
Lechpammer M; Lukac J; Lechpammer S; Kusić Z
Acta Med Croatica; 2002; 56(1):21-6. PubMed ID: 12455450
[TBL] [Abstract][Full Text] [Related]
13. Simple enumerations of peripheral blood natural killer (CD56+ NK) cells, B cells and T cells have no predictive value in IVF treatment outcome.
Thum MY; Bhaskaran S; Bansal AS; Shehata H; Ford B; Sumar N; Abdalla HI
Hum Reprod; 2005 May; 20(5):1272-6. PubMed ID: 15829490
[TBL] [Abstract][Full Text] [Related]
14. [The effect of one-month antithyroid therapy on peripheral metabolism of reactive oxygen species in Graves' disease with infiltrative ophthalmopathy].
Bednarek J; Wysocki H; Sowiński J
Przegl Lek; 2004; 61(8):841-4. PubMed ID: 15789912
[TBL] [Abstract][Full Text] [Related]
15. [Novel treatment of Graves' disease using the B-lymphocyte depleting agent rituximab].
Nielsen CH; El Fassi D; Hegedüs L
Ugeskr Laeger; 2008 Jun; 170(24):2131-4. PubMed ID: 18565295
[TBL] [Abstract][Full Text] [Related]
16. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
Bojarska-Szmygin A; Ciechanek R
Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
[TBL] [Abstract][Full Text] [Related]
17. Serial analysis of the effects of methimazole or radical therapy on circulating CD16/56 subpopulations in Graves' disease.
Rojano J; Sasián S; Gavilán I; Aguilar M; Escobar L; Girón JA
Eur J Endocrinol; 1998 Sep; 139(3):314-6. PubMed ID: 9758442
[TBL] [Abstract][Full Text] [Related]
18. A 6-year follow-up of a randomized prospective trial comparing methimazole treatment with or without exogenous L-thyroxine in Chinese patients with Graves' disease.
Liu X; Qiang W; Liu X; Liu L; Liu S; Gao A; Gao S; Shi B
Exp Clin Endocrinol Diabetes; 2014 Nov; 122(10):564-7. PubMed ID: 25140995
[TBL] [Abstract][Full Text] [Related]
19. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
[TBL] [Abstract][Full Text] [Related]
20. [Prospective study on the relationship between treatment duration of antithyroid drug and remission rate of Graves' disease].
Liu C; Duan Y; Wu X
Zhonghua Yi Xue Za Zhi; 2000 Nov; 80(11):835-7. PubMed ID: 11218878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
